Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. VINGE ADVISES HELLMAN & FRIEDMAN IN CONNECTION WITH THE ACQUISITION OF BAIN CAPITAL’S STAKE IN SECURITAS DIRECT VERISURE GROUP
Mandate

VINGE ADVISES HELLMAN & FRIEDMAN IN CONNECTION WITH THE ACQUISITION OF BAIN CAPITAL’S STAKE IN SECURITAS DIRECT VERISURE GROUP

October 05, 2015

Vinge and Latham & Watkins LLP have advised Hellman & Friedman in connection with the acquisition of Bain Capital’s stake in Securitas Direct Verisure Group. Verisure Securitas Direct is a leading supplier of professionally monitored home alarms, fire alarms and connected services for homes and businesses. The company’s 1.8 million customers are spread over 13 countries in Europe and South America. The transaction is subject to customary regulatory conditions and approvals.

Vinge’s team consisted of partner Jonas Bergström together with, among others, associates Linda Sengul and Carl Sander. Partner Louise Brorsson Salomon and associates Anders Morén and Linn Adelwald provided financing advice in relation to the transaction.

Related

Vinge has advised Morrow Bank AB (publ) in conjunction with the acquisition of MedMera Bank AB

 Vinge has advised Morrow Bank AB (publ) in conjunction with the acquisition of all shares in MedMera Bank AB from Kooperativa Förbundet for a total consideration of SEK 1,960 million. The transaction positions Morrow Bank as a leading Nordic platform in consumer finance with combined gross loans of SEK 28.2 billion.
March 24, 2026

Vinge advises NEWS, a portfolio company of Litorina, in connection with the sale of Skandinavisk Kommunalteknik, FANN VA-Teknik and Alunda Polyeten to Wienerberger AG

 Vinge advises Northern Environmental and Water Solutions AB (“NEWS”), a portfolio company of Litorina, in connection with the sale of the operating subsidiaries Skandinavisk Kommunalteknik, FANN VA-Teknik and Alunda Polyeten to Wienerberger AG (Vienna Stock Exchange: WIE). The transaction is expected to be completed in Q2 2026.
March 24, 2026

Vinge has advised Hansa Biopharma in connection with entering into a financing agreement

 Vinge has advised Hansa Biopharma AB (publ), a commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions, listed on Nasdaq Stockholm, in connection with a U.S. convertible note purchase agreement comprising USD 30 million aggregate principal amount of unsecured convertible senior notes.
March 23, 2026